Search
Search Results
-
Low microsatellite instability: A distinct instability type in gastric cancer?
PurposeWe recently showed that low microsatellite instability (MSI-L) is associated with a good response to platinum/5-fluorouracil (5-FU)...
-
Activation of PI3K/AKT/mTOR signaling axis by UBE2S inhibits autophagy leading to cisplatin resistance in ovarian cancer
BackgroundEpithelial ovarian cancer (OC) is the fourth leading cause of cancer-related deaths in women, with a 5-year survival rate of 30%-50%....
-
Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review
PurposeChemotherapy-induced peripheral neurotoxicity (CIPN) is a common dose-limiting toxicity of cancer treatment causing functional impairment and...
-
Potential of platinum-resensitization by Wnt signaling modulators as treatment approach for epithelial ovarian cancer
PurposeCanonical Wnt/ β-catenin pathway is one mechanism being activated in platinum-resistant epithelial ovarian cancer (EOC). Detecting potential...
-
Phase II trial of combination treatment with S-1/cetuximab in patients with platinum-ineligible recurrent and/or metastatic squamous cell carcinoma of the head and neck
BackgroundThe standard of care for first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) in...
-
Association of CCND1 rs9344 polymorphism with lung cancer susceptibility and clinical outcomes: a case-control study
BackgroundCyclin D1 ( CCND1 ) plays a pivotal role in cancer susceptibility and the platinum-based chemotherapy response. This study aims to assess...
-
The PAPSS1 gene is a modulator of response to cisplatin by regulating estrogen receptor alpha signaling activity in ovarian cancer cells
BackgroundCancer cells may develop resistance to cisplatin by various mechanisms. Yet, the exact mechanism of cisplatin in ovarian cancer remains...
-
Antibody–drug conjugates in ovarian cancer
Ovarian cancer (OC) management presents a challenging scenario in clinical practice due to its late diagnosis, high recurrence rate, and dismal...
-
A novel germline BRCA2 mutation in a Chinese patient with prostate cancer sensitive to platinum chemotherapy: a case report
BackgroundGermline BRCA2 mutation is associated with an aggressive prostate cancer phenotype and indicates higher risk for hereditary cancer....
-
Moving beyond cisplatin resistance: mechanisms, challenges, and prospects for overcoming recurrence in clinical cancer therapy
Cisplatin, a classical platinum-based chemotherapy agent, has been a frontline treatment for various cancers for decades. However, its effectiveness...
-
Veratricplatin inhibits the progression of hypopharyngeal squamous cell carcinoma FaDu cells in vitro and in vivo
PurposeHead and neck squamous cell carcinoma (HNSCC) ranks as the sixth most prevalent cancer. In recent years, the modification of platinum(II) into...
-
Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
Ovarian cancer is the most lethal gynaecologic malignancy. Although there are various subtypes of ovarian cancer, high-grade serous ovarian cancer...
-
Polymorphic renal transporters and cisplatin’s toxicity in urinary bladder cancer patients: current perspectives and future directions
Urinary bladder cancer (UBC) holds a potentially profound social burden and affects over 573,278 new cases annually. The disease’s primary risk...
-
Adipose tissue area as a predictor for the efficacy of apatinib in platinum-resistant ovarian cancer: an exploratory imaging biomarker analysis of the AEROC trial
BackgroundVascular endothelial growth factor (VEGF)-targeted therapy is effective in patients with ovarian cancer. Whether adipose tissue (AT) could...
-
Systematic analysis of ovarian cancer platinum-resistance mechanisms via text mining
BackgroundPlatinum resistance is an important cause of clinical recurrence and death for ovarian cancer. This study tries to systematically explore...
-
Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes
PurposeA 3-biomarker homologous recombination deficiency (HRD) score is a key component of a currently FDA-approved companion diagnostic assay to...
-
Targeting BRCA and PALB2 in Pancreatic Cancer
An important subgroup of pancreatic ductal adenocarcinomas (PDACs) harbor pathogenic variants in BRCA1 , BRCA2 , or PALB2 . These tumors are exquisitely...
-
Effects of SLC31A1 and ATP7B polymorphisms on platinum resistance in patients with esophageal squamous cell carcinoma receiving neoadjuvant chemoradiotherapy
The relationship between the SLC31A1 (protein: copper transporter 1) rs10981694 A > C and ATP7B (protein: P-type adenosine triphosphatase 7B)...
-
Red Cell Distribution Width and High Grade Serous Ovarian Cancer: Prognostic Marker?
PurposeRed cell distribution width (RDW) has been evaluated as a potential prognostic marker in ovarian cancers, with higher baseline values being...
-
Performance of a RAD51-based functional HRD test on paraffin-embedded breast cancer tissue
PurposeBRCA- deficient breast cancers (BC) are highly sensitive to platinum-based chemotherapy and PARP inhibitors due to their deficiency in the...
